The remote control doesn’t trigger the self-destruction of the CAR T cells, but simply prompts them to disengage from their cancerous targets.

Madrigal has made three in-licensing deals since July 2025, picking up multiple potential MASH therapeutics. Read why MDGL ...

A new CAR T therapy design uses the approved drug venetoclax to temporarily disengage engineered immune cells from tumors.

A retrospective study sought to confirm real-world outcomes of patients with HER2+ breast cancer treated with trastuzumab deruxtecan.

Among the most promising tools of cancer therapy, engineered immune cells known as chimeric antigen-receptor (CAR) T cells ...

There's two promising options to make statins tolerable again.

HELUS Pharma has rebranded and moved to Nasdaq, signaling a shift toward late-stage clinical development and commercial focus ...

Bayer's Nubeqa gains approval in India for non-chemotherapy treatment of advanced prostate cancer, enhancing patient care ...

By Vijay Kumar Malesu Emerging evidence suggests that microbial metabolites not only regulate endogenous GLP-1 secretion but may also influence therapeutic response to GLP-1 receptor agonists, raising ...

DoD-Funded Study Accelerates Novel PTSD Mechanism into Trials; Proven Alcohol Safety Profile De-Risks Program for ...